Lineage Cell Therapeutics, Inc.
LCTX
$1.26
$0.097.69%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 76.43% | 19.42% | 6.19% | -0.60% | -41.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.43% | 19.42% | 6.19% | -0.60% | -41.22% |
| Cost of Revenue | -7.43% | -15.68% | -22.68% | 7.56% | 61.42% |
| Gross Profit | 74.26% | 55.61% | 57.44% | -27.77% | -512.21% |
| SG&A Expenses | 28.74% | 28.38% | 31.94% | -16.32% | -20.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.82% | 5.66% | 2.75% | -17.36% | -17.10% |
| Operating Income | 7.57% | -0.47% | -1.30% | 23.23% | 6.33% |
| Income Before Tax | -68.40% | 31.59% | 20.19% | 19.59% | -3.67% |
| Income Tax Expenses | -- | -- | -- | 100.00% | 100.00% |
| Earnings from Continuing Operations | -68.40% | 31.59% | 13.49% | 13.32% | -9.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -1,050.00% | -69.57% | -285.71% | -204.84% | -73.77% |
| Net Income | -69.14% | 31.49% | 13.39% | 12.81% | -9.82% |
| EBIT | 7.57% | -0.47% | -1.30% | 23.23% | 6.33% |
| EBITDA | 7.61% | -0.96% | -1.75% | 23.66% | 6.35% |
| EPS Basic | -35.07% | 41.64% | 22.83% | 18.44% | -3.71% |
| Normalized Basic EPS | -2.82% | 30.55% | 17.58% | 37.50% | 15.38% |
| EPS Diluted | -35.07% | 41.64% | 22.83% | 18.44% | -3.71% |
| Normalized Diluted EPS | -2.82% | 30.55% | 17.58% | 37.50% | 15.38% |
| Average Basic Shares Outstanding | 22.43% | 19.98% | 15.95% | 7.29% | 6.04% |
| Average Diluted Shares Outstanding | 22.43% | 19.98% | 15.95% | 7.29% | 6.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |